How should we best manage patients with immune-mediated inflammatory disease on immunosuppressant therapy during the 'swine flu' pandemic?
Mangat
P
P
Kennedy Institute of Rheumatology Division, Imperial College London and Charing Cross Hospital, Imperial College Healthcare NHS Trust, London W6 8RF, UK. pamela.mangat@imperial.ac.uk
Abraham
S
S
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000627:therapeutic use*; D007251:Influenza, Human / Q000517:prevention & control*; D028761:Withholding Treatment
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D007252:Influenza Vaccines